139 related articles for article (PubMed ID: 37853619)
1. Treatment of dabigatran intoxication in critically ill patients with Acute Kidney Injury: The role of Sustained Low-Efficiency Dialysis.
Pacchiarini MC; Regolisti G; Greco P; Di Motta T; Benigno GD; Delsante M; Fiaccadori E; Di Mario F
Int J Artif Organs; 2023; 46(10-11):574-580. PubMed ID: 37853619
[TBL] [Abstract][Full Text] [Related]
2. Sustained low-efficiency dialysis with regional citrate anticoagulation in critically ill patients with COVID-19 associated AKI: A pilot study.
Di Mario F; Regolisti G; Di Maria A; Parmigiani A; Benigno GD; Picetti E; Barbagallo M; Greco P; Maccari C; Fiaccadori E
J Crit Care; 2021 Jun; 63():22-25. PubMed ID: 33611151
[TBL] [Abstract][Full Text] [Related]
3. Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
Flynn F; Richard G; Dobrescu MA; Bouchard J; Williamson D; Brindamour D; Charbonney E; Dupuis S
J Pharm Pract; 2022 Apr; 35(2):302-307. PubMed ID: 32985337
[TBL] [Abstract][Full Text] [Related]
4. Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients.
Finkel KW; Foringer JR
Ren Fail; 2005; 27(5):541-5. PubMed ID: 16152991
[TBL] [Abstract][Full Text] [Related]
5. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
6. Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury.
Greco P; Regolisti G; Maggiore U; Ferioli E; Fani F; Locatelli C; Parenti E; Maccari C; Gandolfini I; Fiaccadori E
J Nephrol; 2019 Apr; 32(2):297-306. PubMed ID: 30523561
[TBL] [Abstract][Full Text] [Related]
7. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Sheikh-Taha M
Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
[TBL] [Abstract][Full Text] [Related]
8. Hypophosphatemia in critically ill patients undergoing Sustained Low-Efficiency Dialysis with standard dialysis solutions.
Di Mario F; Regolisti G; Maggiore U; Pacchiarini MC; Menegazzo B; Greco P; Maccari C; Zambrano C; Cantarelli C; Pistolesi V; Morabito S; Fiaccadori E
Nephrol Dial Transplant; 2022 Nov; 37(12):2505-2513. PubMed ID: 35481705
[TBL] [Abstract][Full Text] [Related]
9. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
10. Short-and long-term outcomes of sustained low efficiency dialysis vs continuous renal replacement therapy in critically ill patients with acute kidney injury.
Harvey AK; Burns KEA; McArthur E; Adhikari NKJ; Li D; Kitchlu A; Meraz-Munõz A; Garg AX; Nash DM; Perez-Sanchez A; Beaubien-Souligny W; Bagshaw SM; Friedrich JO; Silver SA; Wald R
J Crit Care; 2021 Apr; 62():76-81. PubMed ID: 33290929
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review.
Awesat J; Sagy I; Haviv YS; Rabinovich A; Jotkowitz A; Shleyfer E; Barski L
Thromb Res; 2018 Sep; 169():120-122. PubMed ID: 30032039
[TBL] [Abstract][Full Text] [Related]
12. Sustained low efficiency dialysis is non-inferior to continuous renal replacement therapy in critically ill patients with acute kidney injury: A comparative meta-analysis.
Dalbhi SA; Alorf R; Alotaibi M; Altheaby A; Alghamdi Y; Ghazal H; Almuzaini H; Negm H
Medicine (Baltimore); 2021 Dec; 100(51):e28118. PubMed ID: 34941056
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and Efficacy of Sustained Low-Efficiency Dialysis in Critically Ill Children with Severe Acute Kidney Injury.
Yadav M; Tiwari AN; Lodha R; Sankar J; Khandelwal P; Hari P; Sinha A; Bagga A
Indian J Pediatr; 2023 Apr; 90(4):355-361. PubMed ID: 35781615
[TBL] [Abstract][Full Text] [Related]
14. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
Chan YH; Yeh YH; Hsieh MY; Chang CY; Tu HT; Chang SH; See LC; Kuo CF; Kuo CT
Int J Cardiol; 2018 Aug; 265():83-89. PubMed ID: 29885705
[TBL] [Abstract][Full Text] [Related]
15. Archetypal sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring kidney replacement therapy: towards an adequate therapy.
Sethi S; Mangat G; Soundararajan A; Marakini AB; Pecoits-Filho R; Shah R; Davenport A; Raina R
J Nephrol; 2023 Sep; 36(7):1789-1804. PubMed ID: 37341966
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
Novak JE; Alamiri K; Yee J
Am J Kidney Dis; 2018 Jan; 71(1):137-141. PubMed ID: 28549534
[TBL] [Abstract][Full Text] [Related]
17. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Chan YH; Yeh YH; See LC; Wang CL; Chang SH; Lee HF; Wu LS; Tu HT; Kuo CT
J Am Coll Cardiol; 2016 Nov; 68(21):2272-2283. PubMed ID: 27884245
[TBL] [Abstract][Full Text] [Related]
18. Sustained Low Efficiency Dialysis in Critically Ill Children With Acute Kidney Injury: Single-Center Observational Cohort in a Resource-Limited Setting.
Shiri S; Naik NM; Av L; Vasudevan A
Pediatr Crit Care Med; 2023 Mar; 24(3):e121-e127. PubMed ID: 36508240
[TBL] [Abstract][Full Text] [Related]
19. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Ryan M; Ware K; Qamri Z; Satoskar A; Wu H; Nadasdy G; Rovin B; Hebert L; Nadasdy T; Brodsky SV
Nephrol Dial Transplant; 2014 Dec; 29(12):2228-34. PubMed ID: 24009280
[TBL] [Abstract][Full Text] [Related]
20. Reversal of Dabigatran with Idarucizumab.
Sodha NR; Sellke FW
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
